Loading company
Sutro Biopharma, Inc.
STRO · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$15.98+1.7%Sep 25 close
- 1M
- -21.9%
- 6M
- -34.6%
- 1Y
- +82.6%
- 5Y
- -91.9%
STRO · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$15.98+1.7%Sep 25 close
Sutro Biopharma, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $9.8M | $63.7M | -84.57% |
| Profit | -$38.5M | -$11.5M | -235.10% |
| Profit per share | -$2.33 | -$1.35 | -72.59% |
| Free Cash Flow | -$19.5M | -$6.7M | -189.57% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“During the second quarter, we continued to execute swiftly across our next-generation ADC portfolio, highlighted by encouraging early clinical data from our ongoing Phase 1 study of STRO-004, having rapidly enrolled our initial dose escalation cohorts in just seven months and now optimizing our go-forward dose,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Sutro Biopharma, Inc.’s Item 2.02 8-K filed August 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Sutro Biopharma, Inc. has no earnings call transcript available.